Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
267 Leser
Artikel bewerten:
(1)

Purdue Research Foundation: Purdue innovations detect lead exposure faster, easier and with greater precision at the point of care

Finanznachrichten News

New patent-pending methods use portable XRF analyzers to test bone for chronic exposure and dried blood spots for recent exposure

WEST LAFAYETTE, Ind., Oct. 31, 2024has developed noninvasive methods that detect levels of lead exposure in bone and blood faster, easier and with greater sensitivity at the point of care than traditional methods.
Innovative patent-pending technology created by Aaron Specht, assistant professor in the School of Health Sciences, allows portable X-ray fluorescenceand the March 2021 issue of Environmental Science & Technology, both peer-reviewed publications.
Specht disclosed the innovations to the Purdue Innovates Office of Technology Commercialization, which has applied for patents to protect the intellectual property. Industry partners interested in developing or commercializing them should contact Patrick Finnerty, senior business development and licensing manager - life sciences, at pwfinnerty@prf.org, about track codes 69970and 70284.
Testing bone for lead exposure levels
Exposure to lead can lead to damage to the brain and central nervous system, development and growth delays, learning and behavior problems, hearing and speech problems, reproductive health problems, kidney injury, high blood pressure, anemia, and more.
Specht said the industry standard to measure lead exposure is a blood test.
"That test only measures the past 30 days," he said. "If the test is administered outside that 30-day window, especially in children, you're unlikely to get a result that is reflective of the chronic cumulative activity in the body."


Specht said older technology used to measure bone lead exposure levels has drawbacks including size, expert knowledge, rare elements and speed.
"It weighs about 150 pounds because it requires liquid nitrogen-cooled detectors," he said. "It is incredibly difficult to use; we had trained physicists who would operate the system. It uses a cadmium source, which was produced in Russia, but we can't buy anymore. And it takes 30 minutes to complete one measurement."
Using Specht's method with portable XRFs addresses those drawbacks for bone tests.
"I train people to use this system in 30 minutes. It's a very simple 'point-and-shoot' process, and the XRF analyzer's tablet reads out the results within a few minutes," Specht said. "Once trained, that person will be able to do measurements to identify community-level lead exposures."
Specht said the next step to develop the innovation is getting health leaders' buy-in to use it in national cohort studies and routine surveillance.
"We can then determine what national standards for cumulative lead exposure looks like," he said. "The main argument for continuing to use blood tests is that we have used them in the past, but the advantages for bone in identifying real health consequences should outweigh our stubbornness."
Improving blood tests for lead exposure levels
As with the bone test technology, Specht's innovation to test dried blood spots improves the accessibility for hard-to-reach communities and rural populations. But it also has a better sensitivity than currently available tests.
"The current blood lead measurement technology has a detection limit that is higher than the level that we know causes harm," he said. "That technology may measure as low as 3.5 micrograms per deciliter, but there will be no result for someone slightly below that. Our detection limit is 1 microgram per deciliter, which most experts agree is the level of detection to identify if someone is truly harmed."
The National Institutes of Health, U.S. Department of Defense and the JPB Foundation have provided funding to support Specht's research.
About Purdue Innovates Office of Technology Commercialization
The Purdue Innovates Office of Technology Commercializationoperates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2024, the office reported 145 deals finalized with 224 technologies signed, 466 invention disclosures received, and 290 U.S. and international patents received. The office is managed by the Purdue Research Foundation, a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.orgfor more information.
About Purdue University
Purdue University is a public research institution demonstrating excellence at scale. Ranked among top 10 public universities and with two colleges in the top four in the United States, Purdue discovers and disseminates knowledge with a quality and at a scale second to none. More than 105,000 students study at Purdue across modalities and locations, including nearly 50,000 in person on the West Lafayette campus. Committed to affordability and accessibility, Purdue's main campus has frozen tuition 13 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap - including its first comprehensive urban campus in Indianapolis, the Mitch Daniels School of Business, Purdue Computes and the One Health initiative - at https://www.purdue.edu/president/strategic-initiatives.

Attachment

  • Lead exposure level assessment method, Aaron Specht, Purdue University (https://ml.globenewswire.com/Resource/Download/c2ee707a-666d-4400-838a-33e1d87cf7e3)

© 2024 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.